Metopace XR 50 Tablet contains Metoprolol Succinate 47.5 mg, a cardioselective beta-1 adrenergic receptor blocker indicated for the management of hypertension, angina pectoris, and heart failure. By selectively inhibiting beta-1 receptors in the heart, Metoprolol reduces heart rate, myocardial contractility, and cardiac output, thereby decreasing myocardial oxygen demand and lowering blood pressure. The extended-release formulation ensures a consistent plasma concentration, allowing once-daily dosing for improved patient compliance. Metopace XR 50 is effective in reducing the risk of cardiovascular events such as myocardial infarction and stroke in patients with established cardiovascular disease. It is contraindicated in patients with severe bradycardia, cardiogenic shock, overt heart failure, or known hypersensitivity to beta-blockers. Caution is advised in patients with asthma, diabetes mellitus, and peripheral vascular disease due to potential adverse effects. Common side effects include fatigue, dizziness, hypotension, and gastrointestinal disturbances. Dose adjustments may be necessary in renal or hepatic impairment. Metopace XR 50 should be discontinued gradually to avoid acute tachycardia, hypertension, or ischemia. Clinical monitoring of heart rate, blood pressure, and symptomatology is recommended during therapy to optimize therapeutic outcomes and minimize adverse effects.